Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Primary Peritoneal Carcinoma
Related studies linked through entity extraction aliases.
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
- Status
- UNKNOWN
- Phase
- PHASE3
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
- Status
- WITHDRAWN
- Phase
- N/A
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
- Status
- COMPLETED
- Phase
- NA
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- N/A
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
- Status
- COMPLETED
- Phase
- N/A
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE1